T. Rowe Price Associates
PRAX icon

T. Rowe Price Associates’s Praxis Precision Medicines PRAX Stock Holding History

T. Rowe Price Associates’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$316M Buy
942,999
+312,147
+49% +$98.8M 0.03% 380
2026
Q1 		$203M Sell
630,852
-155,135
-20% -$48M 0.02% 459
2025
Q4 		$232M Sell
785,987
-217,503
-22% -$40.5M 0.03% 424
2025
Q3 		$53.2M Sell
1,003,490
-469,585
-32% -$22.8M 0.01% 794
2025
Q2 		$61.9M Buy
1,473,075
+377,350
+34% +$14.4M 0.01% 678
2025
Q1 		$41.5M Sell
1,095,725
-112,797
-9% -$7.04M 0.01% 775
2024
Q4 		$93M Buy
1,208,522
+88,442
+8% +$6.4M 0.01% 576
2024
Q3 		$64.5M Buy
1,120,080
+181,501
+19% +$9.8M 0.01% 684
2024
Q2 		$38.8M Buy
938,579
+402,580
+75% +$19M ﹤0.01% 796
2024
Q1 		$32.7M Buy
+535,999
New +$24M ﹤0.01% 836
2023
Q2 		– Sell
-2,692
Closed -$33K – 2930
2023
Q1 		$33K Sell
2,692
-504
-16% -$21.3K ﹤0.01% 2824
2022
Q4 		$114K Buy
3,196
+822
+35% +$25.6K ﹤0.01% 2688
2022
Q3 		$81K Sell
2,374
-357
-13% -$17.8K ﹤0.01% 2771
2022
Q2 		$100K Buy
2,731
+896
+49% +$95.6K ﹤0.01% 2754
2022
Q1 		$281K Buy
1,835
+53
+3% +$10.9K ﹤0.01% 2574
2021
Q4 		$527K Buy
1,782
+398
+29% +$117K ﹤0.01% 2363
2021
Q3 		$384K Buy
+1,384
New +$375K ﹤0.01% 2486

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

T. Rowe Price Associates's PRAX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Praxis Precision Medicines (PRAX) stake by 49% in Q2 2026, buying an estimated $98.8M and bringing the position to 942,999 shares worth $316M. The position accounts for 0.03% of the portfolio, ranked #380.

T. Rowe Price Associates first reported a position in PRAX in Q3 2021 and has held it in 17 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • T. Rowe Price Associates held 942,999 shares of Praxis Precision Medicines worth $316M as of Q2 2026.
  • T. Rowe Price Associates bought 312,147 Praxis Precision Medicines shares in Q2 2026, an estimated $98.8M.
  • Praxis Precision Medicines made up 0.03% of T. Rowe Price Associates's portfolio in Q2 2026, its #380 holding.
  • T. Rowe Price Associates first reported a position in Praxis Precision Medicines in Q3 2021 and has held it in 17 quarters since.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.